ATB Therapeutics seeks a Scientist Cell Biology in Ghent
The role is based in the Flemish Region, and the company invites applications or shares of the post with relevant contacts.
See the latest news and media coverage for ATB Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing antibody-based therapies
atbtherapeutics.comLast updated
In short: ATB Therapeutics appointed Mark Throsby CEO to lead its next phase of growth.
The role is based in the Flemish Region, and the company invites applications or shares of the post with relevant contacts.
Throsby, previously Executive Chairman and CSO, leads the company into clinical development as co-founders Magy and Houry become COO and CBO.
The argenx co-founder brings over 30 years of antibody drug development experience. The company also opens a new R&D hub in Gent's VIB Bio-Incubator.
The round is co-led by EQT Life Sciences and MRL Ventures Fund and funds clinical development of oncology and immunology therapies. Mark Throsby joins as Executive Chair.
Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing...
EQT Life Sciences announced that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round aims to accelerate the...
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract development and manufacturing organization...
Track ATB Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ATB Therapeutics and other trending companies.